The Role of Circulating CD16+CD56+ Natural Killer Cells in the Screening, Diagnosis, and Staging of Colorectal Cancer before Initial Treatment
Joint Authors
Cui, Feng
Qu, Di
Sun, Ruya
Tao, Han
Si, Junru
Xu, Yuqing
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-09-17
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Background and Objective.
A reliable noninvasive prediction tool for the screening, diagnosis, and/or staging of colorectal cancer (CRC) before surgery is critical for the choice of treatment and prognosis.
Methods.
Patients admitted for initial treatment of CRC between January 1, 2015, and December 31, 2018, were retrieved and reviewed.
Records of CD16+CD56+ natural killer (NK) cells were analyzed according to the stages of CRC.
Results.
The number of qualified participants in the healthy, stage I, stage II, stage III, and stage IV CRC patients were 60, 66, 60, 70, and 68, respectively.
There was a significant difference in circulating CD16+CD56+ NK cells between the healthy group and the CRC group (p<0.01), as well as between the healthy group and stage III or IV CRC group (p<0.01 and 0.001, respectively).
The percentage of circulating CD16+CD56+ NK cells in lymphocytes was negatively correlated with the occurrence of CRC.
When comparing the pool of stage I and II CRC cases with the pool of stage III and IV CRC cases using circulating CD16+CD56+ NK cells, the area under the Receiver Operating Characteristic curve was 0.878.
Using an optimal cutoff value of 15.6%, the OR was 0.06 (0.03, 0.11), p<0.001, sensitivity was 86.5%, specificity was 72.5%, positive predictive value was 74.2%, and negative predictive value was 85.5%.
Conclusions.
Circulating CD16+CD56+ NK cells can be used as a screening and diagnostic/staging tool for CRC.
American Psychological Association (APA)
Cui, Feng& Qu, Di& Sun, Ruya& Tao, Han& Si, Junru& Xu, Yuqing. 2019. The Role of Circulating CD16+CD56+ Natural Killer Cells in the Screening, Diagnosis, and Staging of Colorectal Cancer before Initial Treatment. Disease Markers،Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1147675
Modern Language Association (MLA)
Cui, Feng…[et al.]. The Role of Circulating CD16+CD56+ Natural Killer Cells in the Screening, Diagnosis, and Staging of Colorectal Cancer before Initial Treatment. Disease Markers No. 2019 (2019), pp.1-5.
https://search.emarefa.net/detail/BIM-1147675
American Medical Association (AMA)
Cui, Feng& Qu, Di& Sun, Ruya& Tao, Han& Si, Junru& Xu, Yuqing. The Role of Circulating CD16+CD56+ Natural Killer Cells in the Screening, Diagnosis, and Staging of Colorectal Cancer before Initial Treatment. Disease Markers. 2019. Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1147675
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1147675